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ABSTRACT
Transcription factor control of cell-specific downstream targets can be
significantly altered when the controlling factor is mutated. We show
that the semi-dominant neonatal anemia (Nan) mutation in the EKLF/
KLF1 transcription factor leads to ectopic expression of proteins that
are not normally expressed in the red blood cell, leading to systemic
effects that exacerbate the intrinsic anemia in the adult and alter
correct development in the early embryo. Even when expressed as a
heterozygote, the Nan-EKLF protein accomplishes this by direct
binding and aberrant activation of genes encoding secreted factors
that exert a negative effect on erythropoiesis and iron use. Our data
form the basis for a novel mechanism of physiological deficiency that
is relevant to human dyserythropoietic anemia and likely other
disease states.
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INTRODUCTION
Direct activation of tissue-restricted gene expression relies on
transcription factors that faithfully recognize their cognate binding
sequence in DNA and influence the transcriptional and epigenetic
outcome (Novershtern et al., 2011). Of special importance for
erythropoiesis is EKLF/KLF1, which exerts a global role in tissue-
specific gene regulation by virtue of its three-finger recognition of
the 9 bp 5′CCMCRCCCN sequence at target gene promoters and
enhancers (reviewed by Siatecka and Bieker, 2011; Tallack and
Perkins, 2010; Yien and Bieker, 2013). Its effects are circumscribed
owing to its tissue-restricted expression in erythroid cells and its
bipotent myeloid progenitor. Genetic ablation studies in the mouse
show that EKLF is absolutely essential because death results from a
profound β-thalassemia and the low to virtually non-existent
expression of global erythroid genes of all categories.
Monoallelic mutation of KLF1 in humans can lead to a benign
outcome that is nonetheless phenotypically important (Borg et al.,
2011; Helias et al., 2013; Singleton et al., 2012; Tallack and Perkins,
2013;Waye and Eng, 2015), as haploinsufficient levels of KLF1 lead
to altered β-globin switching, which can be advantageous in
individuals with β-thalassemia (Liu et al., 2014). However, some
mutations lead to anemias (Arnaud et al., 2010; Huang et al., 2015;
Jaffray et al., 2013; Singleton et al., 2011; Viprakasit et al., 2014;
reviewed by Perkins et al., 2016). The human KLF1 mutation
(E325K) in congenital dyserythropoietic anemia (CDA) (Arnaud
et al., 2010; Jaffray et al., 2013; Singleton et al., 2011) is at the same
amino acid as that seen in the mouseNanmutant (Heruth et al., 2010;
Siatecka et al., 2010b), albeit a different substitution. Nan is inherited
in a semi-dominant fashion: homozygotes die in utero at E10-11,
while heterozygous Nan/+ mice exhibit lifelong severe anemia that is
characterized by reticulocytosis, splenomegaly, altered globin
expression and cell membrane defects (Lyon, 1983; Siatecka et al.,
2010b; White et al., 2009). Transfer of Nan mouse anemic
hematological properties after bone marrow transplantation of Nan/
+ cells to a wild-type recipient shows the dominant, cell-autonomous
nature of the effect (Lyon, 1983; White et al., 2009).
The mutation in zinc finger 2 at E339D, although conservative, is
at a universally conserved amino acid and leads to altered
recognition properties such that Nan-KLF1 recognizes only the
5′CCMCGCCCN subset of wild-type sequences and leads to a
distorted genetic output (Siatecka et al., 2010b). Thus, there are two
types of binding sites: those able to bind both wild-type KLF1 and
Nan-KLF1 (category I) and those able to bind only wild-type KLF1
(category II) (Siatecka et al., 2010b). Paradoxically, the mutant
Nan-KLF1 form interferes with the expression of target genes with
category II sites, to which it can no longer bind. The molecular
explanation behind this remains unclear. However, the change also
confers recognition of an altered sequence that is not normally
associated with KLF1 recognition (Gillinder et al., 2016), such that
genes that are never seen in the erythroid cell are ectopically
expressed in the Nan/+ mutant.
An incompletely explained aspect of the Nan/+ mouse is that its
anemia is wide-ranging during development in both the embryo and
the adult, and may not be completely accounted for by the distortion
in the intrinsic pattern of expression in the Nan/+ erythroid cell. This
is directly relevant to the humans with CDA, who also exhibit a range
of effects that appear extrinsic to those caused by a tissue-restricted
factor such as KLF1. We have addressed these issues by testing the
hypothesis that ectopic expression of a specific subset of genes leads
to effects that are superimposed on the red cell defects and thus plays
a significant contributory role to the Nan anemia phenotype.
RESULTS
Altered recognition sequences of Nan-EKLF lead to
circumscribed and ectopic/neomorphic gene expression in
the Nan/+ mouse fetal liver erythroid cell
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Fig. 1. Expression of EKLF (KLF1) targets in fetal liver
samples. (A-C) RNA-seq expression data of E13.5 fetal liver
cells fromwild-type (+/+) (dark gray) and Nan/+ (red) littermates
(‘Nan’), or from wild-type (+/+) (light gray) and EKLF-null (−/−)
(blue) littermates were analyzed for expression of target genes.
Each is an average of biological triplicate samples. (A) Genes
containing category II (Ebp4.9, E2f2) or category I (Alas2)
target sites (as defined by Siatecka et al., 2010b; examples are
shown in Table S1) were analyzed for expression.
(B) Expression of embryonic βh1 globin (Hbb-bh1) and adult β
globins (Hbb-b1 and Hbb-b2) show target gene dysregulation.
(C) Expression level of novel targets hepcidin (Hamp) and Irf7,
which are most dramatically increased in the Nan/+ samples,
are shown next to a representative browser expression profile
from one sample each [wild type (+/+) (dark gray) and Nan/+
(red)]. In each case, expression of the adjacent genes is
unaffected by Nan-EKLF expression status. (D) Expression of
total EKLF (Klf1) in the Nan littermates is shown for
comparison; this analysis does not differentiate between wild-
type and Nan-EKLF RNA. (E) Total RNA from adherent cell-
depleted and expanded erythroid cells isolated from wild-type
(+/+) or Nan/+ littermates (‘Nan’) were monitored by q-RT-PCR
for expression of EKLF (Klf1), Ebp4.9, hepcidin (Hamp) or Irf7.
Results are the average of three biological replicates each
performed in triplicate.
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(Gillinder et al., 2016) support the initial genotypic analysis of theNan
mouse (Siatecka et al., 2010b), showing a dysregulated erythroid
transcript pattern in spite of the heterozygosity of the KLF1mutation.
For example (Fig. 1A), expression of dematin (Epb4.9, also known as
Dmtn) and E2f2 are virtually absent in KLF1 knockout cells, and this
is mimicked inNan/+ cells; these contain category II elements that are
affected by the presence of Nan-KLF1. As a control, Alas2, which
contains a category I-binding element, is not altered in Nan/+ cells
comparedwith wild type. Finally, hemoglobin switching is altered, as
embryonic Hbb-bh1 globin expression is retained at high levels in
both knockout andNan/+ E13.5 fetal liver, whereas adultHbb-b1 and
Hbb-b2 globin expression are 50-70% less (Fig. 1B), as previously
observed (Siatecka et al., 2010b). Although many of these changes
arise from themore-limited target DNA sequence recognized byNan-
KLF1 protein (i.e. 5′CCMCGCCCN) compared with wild type (i.e.
5′CCMCRCCCN) (Siatecka et al., 2010b), our recent studies show that
there is a second consequence of the E339D mutation in Nan-KLF1,
namely that a different recognition sequence (5′CCMNGCCCN) is
newly recognized (Gillinder et al., 2016). We considered whether this
might play an additional role in the anemia and the phenotypic
properties observed throughout development in Nan/+ embryos and
adults, specifically whether the new targets would give rise to aberrant
expression of unusual/unexpected proteins in Nan erythroid cells that
yield deleterious effects.
We began by focusing on the relatively small number (∼80) of
genes that are newly and most highly expressed in Nan/+ cells
compared with wild type (Gillinder et al., 2016), and further parsed
this to genes that are secreted and thus could systemically affect
normal erythropoiesis via the circulation. Two genes in particular
caught our attention. Hepcidin is a regulator of cellular iron use by
virtue of its interaction with ferroportin (Ganz, 2011), and is
primarily expressed in the adult liver. Interferon regulatory factor 7
(IRF7) is a transcription factor primarily expressed by macrophages
that mediates inflammation by virtue of its activation of interferon β
(IFNβ) (Ford and Thanos, 2010; Honda et al., 2005). Misexpression
of either of these would be detrimental to effective erythropoiesis
(Ganz and Nemeth, 2012; Kim and Nemeth, 2015; Nagata, 2007;
Yoshida et al., 2005a). Our data show little expression in the wild-
type or knockout cells or in the wild-type cells from the Nan strain;
however, their levels are dramatically increased in the Nan/+ cells
(Fig. 1C) [also observed in an independent experiment (Fig. S1A),
thus providing us with data from a total of 12 biological replicates].
These are not the result of global or regional changes; in each case,
expression of the adjacent genes remain unaffected irrespective of
the genotype (Fig. 1C). Total KLF1 levels are only slightly lower in
Nan/+ compared with wild type (Fig. 1D and Fig. S1B).
Although EKLF expression is restricted to erythroid progenitors
and their progeny, we verified that the ectopic expression results from
the erythroid compartment by depleting adherent cells and expanding
E13.5 fetal liver cells in erythropoietin. qRT-PCR analysis of RNA
shows that these erythroid-enriched cells express KLF1 at similar
levels, that Nan/+ cells exhibit the dramatic decrease in dematin
(Epb4.9) expression previously seenwith total fetal livermaterial, and
that there is dysregulation of hepcicin (Hamp) and Irf7 (Fig. 1E). We
conclude thatHamp and Irf7 aremis-expressed in the erythroid cell by
virtue of the presence of the Nan mutant variant of KLF1.
Erythroferrone is a new EKLF target that is part of the
disrupted intrinsic expression pattern generated in the Nan-
EKLF red cell
Hepcidin levels are suppressed by erythroferrone (Fam132b) (Kautz
et al., 2014), a gene whose expression in the erythroid cell is
stimulated by erythropoietin when iron mobilization is desired. We
found that erythroferrone is regulated by KLF1 levels in the
erythroid cell, as its expression is virtually absent in the knockout
(Fig. 2A). Of relevance here, its levels are also dramatically
deficient in Nan/+ cells (Fig. 2A,B; Fig. S1C); as with other
similarly affected genes (Siatecka et al., 2010b), this is not due to
haploinsufficient levels of wild-type EKLF (not shown). The two
likely KLF1-binding sites in this gene are category II (Siatecka
et al., 2010b), and thus are predicted to be negatively affected by the
presence of the Nan variant.
The implication that erythroferrone is a KLF1 target was directly
tested using the KLF1-null rescue system with which stably
expressed cytoplasmic ER/KLF1 or ER/ Nan-KLF1 can be induced
to translocate to the nucleus by treatment of the cells with tamoxifen
(Coghill et al., 2001; Hodge et al., 2006). Although the treatment
protocol is limited to 1 h, these rescued cells show robust chromatin
association by ER/KLF1 to one of these sites (a category II site in
intron 1) but not by ER/Nan-KLF1 (Fig. 2C). In addition, RNA
begins to accumulate within this short time period only in the wild-
type rescue (Fig. 2D).
We found additional evidence for disarray in iron utilization
components within the Nan/+ erythroid cell (Gillinder et al., 2016).
For example, when comparing Nan/+ cells with wild type we see a
slight decrease in transferrin receptor (Tfrc) levels, and a slight
increase in ferroportin (Slc40a1) in spite of the increase in hepcidin
(Fig. 3A). This yields a lower level of iron in the red cell (Ganz and
Nemeth, 2012; Tolosano, 2015). Coupled to this, heme oxygenase
(Hmox1) levels increase while heme transporter HRG1 (Slc48a1)
levels decrease in the Nan/+ cells compared with wild type
(Fig. 3B), yielding less heme in the erythroid cell (Korolnek and
Hamza, 2015; Narla and Mohandas, 2015).
In light of this, we examined expression patterns of other genes
involved in iron utilization or in the inflammation pathway
(reviewed by Ganz, 2011; Ginzburg and Rivella, 2011; Guida
et al., 2015; Kim and Nemeth, 2015; Li et al., 2014; Nagata, 2007;
Rivella, 2015; Yoshida et al., 2005b) to address indirect or Nan-
KLF1-independent causes for the inefficient erythropoiesis
(Gillinder et al., 2016). Expression is either unchanged
[hemochromatosis (Hfe), IRP1 (Aco1), aconitase (Aco2), Flvcr1
(Mfsd7b); Fig. S2A] or remains insignificantly expressed [Bmp6,
hemojuvelin (Hfe2), Gdf11, Pigf; not shown]. Genes involved in
regulation of hepcidin, such as Tmprss6, are not altered (Fig. S2B)
or not expressed (Gdf15, Atoh8 and Sox2; not shown), although the
level of Stat3, an upstream regulator of hepcidin, is increased in
Nan/+ cells (Fig. S2B) in spite of undetectable Il6 (not shown).
Levels of erythroid regulators such as Twsg1, HIF2α (Epas1), or
IRP2 (Ireb2) are not altered (Fig. S2C). With respect to genes
involved in a predicted inflammatory response due to Irf7
expression, we see no change in expression of Irf3, Irf2 or Tlr2
(Fig. S2D), and no expression of Tlr6 (not shown). We conclude
that the misexpression of hepcidin and IRF7, and the depletion of
erythroferrone expression in the red blood cell are not the result of a
generalized response to external stimuli but rather are caused by the
intrinsic presence and inappropriate binding of Nan-KLF1.
Effects of Nan-EKLF expression early in development
Embryos that express only the Nan-EKLF variant (i.e. Nan/Nan or
Nan/−) are lethal by E10-11 and display a striking dysmorphology
that extends beyond the fetal erythroid cell (Heruth et al., 2010). To
model these early stages, we established embryonic stem cells
(ESCs) from Nan/Nan and +/+ littermates and differentiated
them to embryoid bodies (EBs). EBs synchronously recapitulate
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erythropoiesis (Choi et al., 2005; Kennedy and Keller, 2003); in our
hands, the onset of Klf1 and primitive erythropoiesis begins at day 4
and peaks by day 6, when definitive erythropoiesis is well underway
to eventual dominance (Adelman et al., 2002; Bruce et al., 2007;
Lohmann and Bieker, 2008). Nan/Nan EBs demonstrate
morphological defects by day 6 of differentiation, as they are
smaller in comparison with +/+ EBs (Fig. 4A). Although the onset
of the CD44 early definitive erythroid cell surface marker (Chen
et al., 2009; Liu et al., 2013) is normal in both sets by day 6 (Fig. 4B,
left), Nan/Nan EBs are defective in generating late (primitive or
definitive) erythroid cells, as judged by the absence of Ter119
expression in these cells at day 6 or day 7 (Fig. 4B, left), which
attains normal levels (Lohmann and Bieker, 2008; Soni et al., 2014)
in the wild-type EBs.
Although this may result from an intrinsic erythroid deficit, we
also tested whether the Nan cells could exert an extrinsic effect on
wild-type EB differentiation by mixing equivalent numbers of +/+
andNan/Nan cells at d0 and then monitoring erythroid status during
differentiation via cell surface marker analysis as before. Again,
although CD44 levels are not affected, no evidence of Ter119
expression is evident even though the number of +/+ cells included
in the culture was no different from before (Fig. 4B, right). We
conclude that the dysmorphology of the non-erythroid tissues seen
in the Nan embryo may well result from the ectopic expression
pattern and resultant secretory proteins seen within the Nan-
expressing cell.
Effects of Nan-EKLF expression in the adult
We next addressed whether the altered expression patterns of Hamp
and Irf7 seen in the fetal liver are also manifested in the Nan/+ adult,
and could explain part of the anemia exhibited by the Nan mouse.
The adult Nan/+ mouse exhibits low mean corpuscular volume and
mean corpuscular hemoglobin, reticulocytosis and splenomegaly
(Siatecka et al., 2010b), suggesting defective erythropoiesis
possibly due to iron deficiency (Andrews, 2009). Consistent with
this, circulating erythropoietin levels are higher inNan/+ adults than
Fig. 2. Altered expression of erythroferrone (Fam132b) in Nanmice fetal liver samples or rescuedEKLF-null erythroid cells. (A) RNA-seq expression data
from biological triplicates of wild-type (+/+) (dark gray) and Nan/+ (red) littermates (‘Nan’), or from wild-type (+/+) (light gray) and EKLF-null (−/−) (blue) littermates
were analyzed for expression of Fam132b (erythroferrone). A representative browser expression profile from one sample each is shown [wild type (+/+) (dark gray)
and Nan/+ (red)]; the adjacent gene is unaffected by Nan-EKLF expression status. A flow chart showing the relationship of erythroferrone to upstream and
downstream effectors is shown on the right. (B) Total RNA from adherent cell-depleted erythroid cells isolated from wild-type (+/+) or Nan/+ littermates (‘Nan’)
were monitored by q-RT-PCR for expression of Fam132b (erythroferrone). Results are the average of three biological replicates each performed in triplicate.
(C) EKLF-null erythroid cells were used to monitor EKLF association with Fam132b chromatin (ChIP) after a 1 h tamoxifen-induced rescue with wild-type
EKLF (K1ER-A) or Nan-EKLF (K1NanER-B) (Coghill et al., 2001); Alas2 wasmonitored as a positive control. Analysis is limited to 1 h post-treatment to avoid loss
of cell number following KLF1 induction of CDK inhibitors and the ensuing cell cycle arrest (Pilon et al., 2008; Siatecka et al., 2010a; Tallack et al., 2009, 2007;
Gnanapragasam et al., 2016). Results are representative of two experiments. (D) RNA expression was monitored across the Fam132b locus during a 1 h
tamoxifen-induced rescuewith thewild-type EKLF (K1ER-A), Nan-EKLF (K1NanER-B) or parental K1 line; treatment with ethanol (EtOH) is the negative control in
each case. 4-Thiouridine tagging was used to identify nascent RNA (Gillinder et al., 2016). Results are representative of two experiments.
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in matched littermates (Fig. 5A). Hamp and Irf7 expression levels
are significantly higher in spleen and bone marrow RNA from the
Nan/+ mouse than in the wild type (Fig. 5B) (although hepcidin
expression is lower in bone marrow than in spleen). To probe the
possibility of systemic changes, we monitored serum levels of
hepcidin and found that its levels are significantly increased in the
circulation in Nan/+ mice compared with wild type (Fig. 5A).
Analysis of serum IFNβ levels show an even more dramatic change
(Fig. 5A). Serum analyses in the adult reflect alterations in the iron
use components we had observed in the Nan/+ fetal erythroid cell
(Fig. 3), as there is a slight but significant increase in serum bilirubin
and a decrease in serum iron (Fig. 5C). Together, these add up to an
iron- and heme-deficient red cell environment that contributes to the
overall anemia of the mouse.
Increased hepcidin production can be achieved by IL6-mediated
stimulation of the liver, particularly as a result of an inflammatory
response (Nemeth et al., 2004a). As a result, we checked for IL6
in the serum, but did not find any detectable levels in either the
wild-type or Nan/+ adult (Fig. 5D). This removes inflammation as a
causal effector and negates a possible liver contribution to the
circulatory hepcidin levels we see in the Nan/+ adult.
Collectively, the developmental data suggest that the anemia in
adult Nan/+ mice is exacerbated not only by the intrinsic defects in
erythroid expression based on the category I versus category II
distinction, but also by the neomorphic genetic output via the new
recognition site. This leads to expression of secreted molecules that
work directly against establishing a steady-state replenishment of
erythroid cells to combat the anemia.
In vitro and in vivo testing of altered DNA binding by Nan-
EKLF protein in the Nan/+ adult
The DNA-recognition properties of the Nan-KLF1 protein variant
(Gillinder et al., 2016) suggest a possible mechanism for the effect;
i.e. by binding to novel target site(s) within theHamp and Irf7 genes
not normally recognized by the wild-type KLF1 protein. Inspection
of the gene loci of Hamp and Irf7 reveal a number of potential Nan-
KLF1 target sites (5′CCMNGCCCN) that meet this criterion
(Fig. 6A). A subset were tested in vitro by quantitative gel shift
assays for binding to wild-type or Nan-KLF1 proteins. As controls,
we obtained dissociation constants for known category I (p21 site 3)
and category II (dematin and E2F2 site 2) DNA sites binding to
wild-type or Nan-KLF1 protein (Fig. 6B). Using this approach, we
monitored binding to the predicted new sites in the hepcidin (Hamp)
and Irf7 genes and found that binding affinities are substantially
higher for Nan-KLF1 compared with wild type (Fig. 6C),
supporting the predictions made from the global variant analysis.
As a final test, we checked for in vivo interaction of KLF1 or Nan-
KLF1 to these new sites. As we do not have an antibody that can
distinguish wild-type KLF1 from Nan-KLF1, we simply monitored
whether the adult Nan/+ spleen shows a novel KLF1 ChIP
compared with wild type at any of the potential sites of Hamp
and Irf7. KLF1 is well expressed within the red pulp of the normal
adult spleen (Miller and Bieker, 1993; Southwood et al., 1996). The
analyses (Fig. 6D) show that the putative sites are indeed occupied
Fig. 3. Expression of iron- and heme-utilization targets in fetal liver
samples. (A,B) RNA-seq expression data from biological triplicates of wild-
type (+/+) and Nan/+ littermates (‘Nan’) were analyzed for expression of genes
coding for iron (A) and heme (B) transport proteins as indicated.
Fig. 4. Effects of Nan on embryoid
body differentiation. Embryonic stem
(ES) cells derived from wild-type (+/+) or
Nan/Nan littermates were differentiated
to embryoid bodies (EBs) and analyzed
at day (d) 4, d6 or d7.
(A) Photomicrographs of d6 EBs
concurrently generated fromwild-type or
Nan/Nan ES cells (same magnification).
(B) Cell-surface marker expression of
CD44 (early erythroid) and Ter119 (late
erythroid) was performed on d4, d6 or d7
EBs concurrently generated from wild-
type or Nan/Nan ES cells. (Left) Results
from individual cultures. (Right) Results
after having mixed equivalent numbers
of ES cells (wild type with Nan/Nan as
indicated) at d0.
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only in the chromatin derived from the Nan/+ mouse. Collectively,
the in vitro and in vivo data demonstrate that the variant DNA
recognition property of Nan-KLF1 is responsible for altered binding
and subsequent ectopic protein expression in the Nan/+ erythroid
cell.
DISCUSSION
Our studies demonstrate that an apparently minor conservative
change in a single amino acid (E to D) of a crucial erythroid
transcription factor can result in significant phenotypic changes. In
Nan-KLF1, the residue in question is absolutely conserved across
the whole KLF family in all species examined. This leads to a
limitation on its ability to recognize the consensus wild-type DNA
element (Siatecka et al., 2010b). However, a remarkable finding
from the global analyses was that a novel, atypical site is newly
recognized (Gillinder et al., 2016), leading to a significant number
of expressed genes that are not normally present in the mammalian
red cell. We have shown how this can lead to defects of gene
expression within and outside the cell.
Within the wild-type erythroid compartment, neither hepcidin
nor IRF7 is expressed. However, unanticipated phenotypic
changes arise from two physiologically nonproductive cycles
generated by the Nan/+ red cell (Fig. 7). In one case,
misexpression of hepcidin and deficient expression of
erythroferrone lead to a decrease in iron availability and lower
red cell numbers. In the second case, misexpression of IRF7
induces IFNβ expression, which has a repressive effect on
erythroid development. The organism responds to the defects by
inducing erythropoietin to replenish erythropoiesis, leading to
splenomegaly. However, this is futile, as the very cells being
expanded are those that are secreting hepcidin and IFNβ, leading
to an ill-designed feedback inhibition. This cycle is superimposed
upon the intrinsic erythroid deficits, leading to a worsening of
the red cell anemia. The increase in hepcidin is both direct
(via binding of Nan-EKLF to its atypical site) and indirect (via low
erythroferrone expression in the Nan/+ environment), as ablation
of EKLF (and thus low erythroferrone) is not sufficient to
substantially increase hepcidin levels. Remarkably, these deficits
occur even in the presence of a normal wild-type copy of KLF1.
More globally, iron is indispensable for all tissues, being a crucial
component of essential enzymes and multiprotein complexes that
contain heme and iron-sulfur clusters (Zhang et al., 2014). As a
result, heme-containing proteins play crucial roles in all cells
(Sawicki et al., 2015); however, heme can also play lineage-specific
roles in differentiation (Philip et al., 2015). Proper heme levels are
also crucial for normal fetal development, as defects can lead to
limb deformities in addition to abnormal erythropoiesis (Keel et al.,
2008). Not surprisingly then, increased circulatory hepcidin can
have systemic effects; for example, decreasing heme- and nonheme-
iron absorption to the duodenum (Cao et al., 2014). In the present
case, the levels of hepcidin in the Nan/+ mouse are high enough to
exert a physiological effect (Nemeth et al., 2004b).
Fig. 5. Analysis of expression changes in adult Nan/+ mice. (A) Sera from wild-type (+/+) or Nan/+ adult littermates (‘Nan’) were monitored for expression of
erythropoietin (EPO) (n=6, each analyzed at three dilutions, P<0.0001), hepcidin (n=11, each analyzed in duplicate, P<0.0001) or IFNβ (n=4, each analyzed in
duplicate, P=0.049). Data are average±s.e.m. (B) Spleen and bone marrow RNA from wild-type (+/+) or Nan/+ adult littermates (‘Nan’) was monitored by
qRT-PCR for expression of hepcidin (Hamp) or Irf7. Results are from two experiments each performed in triplicate and analyzed at the same time. Although Irf7
is regulated differently in the adult bone marrow compared with the fetal liver (Kingsley et al., 2013; Liang et al., 2015), its levels are nonetheless
significantly increased in the adult Nan/+ bone marrow. (C) Sera from wild-type (+/+) or Nan/+ adult littermates (‘Nan’) were monitored for expression of bilirubin
(n=10-12, P<0.0001) or iron (n=5-7, P=0.0025). Data are average±s.e.m. (D) Sera from wild-type (+/+) or Nan/+ adult littermates (‘Nan’), were monitored for
expression of IL6 (n=8, each analyzed at two dilutions as indicated) and compared with IL6 standards (duplicates are shown).
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As a result, we suggest that Nan-EKLF expression contributes to
the dysmorphology of Nan embryos seen during early stages of
development and during ES cell differentiation, to the fetal liver
erythroid misregulation, and to the chronic anemia of the adult
(Fig. 7). In this context, it is of interest that a DAVID analysis of the
most significantly upregulated gene categories in Nan/+ RNA
shows that those in the ‘secreted’ and ‘signal’ groupings are the
most numerous (Fig. S3).
Intriguingly, low iron availability via hepcidin expression
coupled with expression of IFNβ resembles the anemia of chronic
Fig. 6. Binding of Nan-EKLF to novel genomic regions. (A) Localization of wild-type EKLF binding consensus (5′CCMCRCCCN) or Nan-EKLF-binding
consensus (5′CCMNGCCCN) across the hepcidin (Hamp) and Irf7 genomic loci are shown. Circled regions (red) show the location and sequences used for
further analysis: Hamp-1, Hamp-2 and Irf7-5 (right). (B) In vitro quantitative gel-shift analyses were performed to assess the binding affinities of wild-type and
Nan-EKLF proteins to representative category I (at the p21 gene) or category II (ECR1 at the dematin gene and E2f2 site 2) elements (Siatecka et al., 2010b).
Multiple DNA concentrations were tested and selected, as described in the Materials and Methods: 12.5 to 50 nM for p21 (P=0.32, not significant), 25 nM for
ECR1 (P=0.0045), and 0.5 to 12.5 nM for E2f2 site 2 (P=0.0052), all by unpaired t-test. Excel Solver software was used to determine Kd values along with the
standard deviation (s.d.); SLS is the sum of the squares of the errors and indicates the range of error over the curves. Also shown (as inserts on the p21 data) are
typical gel data generated and analyzed for all the experiments. GST alone showed no binding to any of these probes (not shown). These provide us with a range
of well-discriminated affinities, with nanomolar binding constants that are equivalent at p21 but are 2- (E2F2) to 3.5- (dematin) fold higher with Nan-KLF1
compared with wild type. (C) In vitro quantitative gel shift analyses were performed to assess the binding affinities of wild-type and Nan-EKLF proteins to the novel
Hamp-1, Hamp-2 and Irf7-5 elements. All were analyzed at 5 nM DNA, except Hamp1 ‘EKLF 2’ and IRF7-5 ‘EKLF 2’, which were at 25 nM. (D) In vivo chromatin
immunoprecipitation was performed at selected regions (as shown in A) with IgG (I) or 7B2 anti-EKLF (E) antibodies. Necdin was included as a negative control.
Spleens from wild-type (+/+) or Nan/+ adult littermates (‘Nan’) were used for the analyses. Results are from two separate experiments, each performed in
triplicate.
436
RESEARCH ARTICLE Development (2017) 144, 430-440 doi:10.1242/dev.145656
D
E
V
E
LO
P
M
E
N
T
inflammation (Goodnough et al., 2010), where iron restriction
sensitizes cells to the inhibitory effects of inflammatory cytokines
(Richardson et al., 2013). However, we do not detect any IL6, the
key inducer of hepcidin and mediator of inflammation (Hom et al.,
2015; Wang and Babitt, 2016).
To our knowledge, finding genetic effects of a tissue-restricted
factor that occur outside of its normal expression realm is novel, and
thus may be an unrecognized contribution to human disease. In the
present case, the most direct connection is with CDA type IV
(Iolascon et al., 2012), which is caused by a mutation in human
KLF1 at the same amino acid (Arnaud et al., 2010; Jaffray et al.,
2013; Singleton et al., 2011). The change is non-conservative (E toK),
so although not all characteristics of the Nan mouse may apply,
individuals with CDA exhibit altered globin switching and
membrane deficits that are highly reminiscent of the present
model (discussed by Siatecka et al., 2010b). Of greater interest are
the non-erythroid aspects of a subset of these individuals, such as
short stature, high serum iron and bilirubin levels, and altered
gonads. These suggest that there may very well be secreted factors
that are aberrantly/ectopically expressed in these human cells as a
direct result of the single amino acid change seen in the human
KLF1 CDA mutant.
It may appear surprising that Nan-KLF1 is able to recognize its
atypical site within genes that are presumably not easily accessible
outside their normal cell of expression. However, recent studies
with KLF4, which is highly related to KLF1 (Bieker, 2001),
suggest that zinc fingers 2 and 3 play a necessary and dominant
role in targeting its recognition site within nucleosomes (Soufi
et al., 2015). In the present case, the amino acid change is located
within zinc finger 2 and thus could enable Nan-KLF1 to play a role
as a pioneer factor at ectopic sites in spite of their lower
accessibility in the red cell.
Our present studies, as with the earlier analyses of the Nan-KLF1
protein gene regulation (Siatecka et al., 2010b), re-emphasize that
the effects of KLF1 mutation are not strictly due to a dominant-
negative outcome. This is clearly different from the cell-intrinsic
defects seen with the haploinsufficient or most of the other mutant
KLF1 proteins that have been identified in humans (Borg et al.,
2011; Helias et al., 2013; Perkins et al., 2016; Singleton et al., 2012;
Tallack and Perkins, 2013; Waye and Eng, 2015). What is seen in
the present case is a new variant with novel properties that
dramatically changes Nan/+ red cell identity.
MATERIALS AND METHODS
General protocols
Establishment of the Nan mouse strain has been previously described
(Heruth et al., 2010; Lyon, 1983; Siatecka et al., 2010b). All protocols
have been reviewed and approved by the IACUC at Mount Sinai. RNA
was isolated from E13.5 fetal livers or adult spleens using Trizol. Total
RNA was purified with a Qiagen RNeasy kit. qRT-PCR was performed
using published procedures (Siatecka et al., 2010b). Global RNA-seq
was performed by the Mount Sinai Facility or by the JAX facility and
analyzed as described (Gillinder et al., 2016). The DAVID analysis
tool v6.7 (https://david-d.ncifcrf.gov/) was used as described (Huang
et al., 2009).
Fig. 7. Summary andmodel of systemic and intrinsic effects of the Nan-EKLFmutation. (A) (Left) During normal wild-type steady-state, adult erythropoiesis
is kept in balance by the levels of hepcidin, which negatively regulates iron availability when erythroblast levels are replete, but is negatively regulated by
erythroid erythroferrone when iron is needed for erythroid expansion, such as after stimulation by erythropoietin. (Right) In the case of Nan/+ adults, the direct
increase of hepcidin by Nan-EKLF (a) and the low level of expression of erythroferrone (b) decrease iron availability, negatively affecting erythroblast
expansion. Coupled to this, misexpression of Irf7 (c) leads to secretion of IFNβ, superimposing another negative cycle on erythroid expansion. The net result is a
stimulation of erythroblast proliferation and the accompanying splenomegaly that is non-productive and does not address the anemia, which remains chronic.
These effects in the adult form part of an array of developmental deficits that occur in spite of the erythroid-restricted expression of Nan-EKLF, including
dymorphology in the embryo and embryoid body, and defective erythropoiesis in the fetal red cell. (B) Coupled to the systemic effects summarized in A, intrinsic
expression changes (based on fetal liver expression, although also likely in the adult) in the Nan/+ red cell contribute to defective erythropoiesis by altering genes
that play roles in heme and iron uptake.
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Cell isolation and manipulation
K1-ER or K1-Nan-ER cells (originally described by Coghill et al., 2001,
recently authenticated and reanalyzed by Gillinder et al., 2016) were grown
and treated with doxycycline as described (Coghill et al., 2001; Hodge et al.,
2006). Analysis is limited to 1 h post-treatment to avoid loss of cell number
following KLF1 induction of CDK inhibitors and the ensuing cell cycle
arrest (Gnanapragasam et al., 2016; Pilon et al., 2008; Siatecka et al., 2010a;
Tallack et al., 2009, 2007). As a result, only immediate-early effects can be
detected. Nascent RNA expression was monitored after a concurrent 1 h
treatment of cells with 4-thiouridine, as described previously (Gillinder
et al., 2016).
Mouse ESCs derived from wild-type and Nan/Nan blastocysts
(littermates) were established as described previously with minor
modifications (Meissner et al., 2009). These were maintained and
differentiated to embryoid bodies as per established protocols (Choi et al.,
2005; Kennedy and Keller, 2003) described previously (Manwani et al.,
2007). Ter119-PE and CD44-FITC antibodies were from eBiosciences.
Erythroblasts were derived from wild-type and Nan/+ E12.5 fetal livers
and depleted of adherent cells as previously described (England et al., 2011;
Gnanapragasam et al., 2016). Briefly, cells were harvested, and plated on
gelatin dishes for 2 days. This was followed by a 1-day culture in erythroid
growth media prior to harvest for RNA analysis.
ChIP analysis of EKLF binding was performed using a modification of
previous procedures (Lohmann and Bieker, 2008; Siatecka et al., 2015).
Briefly, cells from fetal livers or spleens (7-10×106 per
immunoprecipitation) were crosslinked with 1.0% formaldehyde.
Chromatin was sonicated, immunoprecipitated with antibodies against
mouse IgG (557273; BD Pharmingen) or EKLF (7B2), and purified on
magnetic protein G Dynabeads (10004D; Life Technologies). Eluted and
precipitated genomic DNA was amplified and quantified by PCR.
Serum testing
Serum from adult mice was analyzed using ELISA kits for erythropoietin
(R&D Systems), IL6 (Thermo Fisher), hepcidin (Intrinsic Lifesciences) or
IFNβ (PBL Assay Science), following the manufacturers’ instructions.
Bilirubin and iron were measured on a Beckman Coulter AU680 Chemistry
Analyzer; only samples with low hemolysis [i.e. hemoglobin value lower
than 100 (Beckman-Coulter)] were used for these analyses.
Quantitative protein-DNA binding analysis
Quantitative gel shifts were performed using GST-tagged EKLF zinc fingers
(Bieker and Southwood, 1995), purified as previously described (Soni et al.,
2014) and incubated with 32P-labeled DNA oligonucleotide probes in
25 mM HEPES (pH 7.5), 16 mM KCl, 50 mMNaCl, 2 µM ZnCl2, 0.6 mM
β-mercaptoethanol and 8% glycerol for 30 min on ice at various
concentrations (see figures and legends). A 10-fold molar excess of
polydeoxyinosinic-deoxycytidylic acid (dIdC, Sigma-Aldrich) relative to
the DNA probe was used to reduce non-specific binding. Protein
concentrations were determined by saturation binding to the p21 gene
EKLF site, to which both EKLF ZF and Nan ZF bind similarly. A fixed
amount of DNA was incubated with increasing amounts of protein and
DNA, and protein concentrations were adjusted to maximize the curve fits.
Samples were electrophoresed on 8% acrylamide gels in 0.5× TBE at 150
volts for 1.5 h at room temperature. Quantitation was performed on a
Molecular Dynamics Phosphorimager. Kd values were determined by curve
fitting with Excel Solver using the following equation and minimizing the
squared error by varying Kdis:
Fraction of DNAbound
¼ Dtot þ Ptot þ Kdis 
p½ðDtot þ Ptot þ KdisÞ2  4  Dtot  Ptot
2  Dtot ;
where Dtot is the DNA concentration, Ptot is the protein concentration, and
Kdis is the dissociation constant. Results for E2f2 site 2 and wild-type EKLF
in Fig. 6B appear more variable than others because different amounts of
poly(dIdC) were used (20- to 400-fold molar excess) to counteract non-
specific binding that occurred at high protein to DNA ratios. The four best
fits (SLS≤0.045) using 0.5 to 2.5 nM DNA and poly(dIdC) were averaged.
For high-affinity binding, DNA amounts were chosen such that 70 to 100%
of the probe was bound at highest protein concentration and there was
detectable binding in the low protein samples: once established, these same
conditions were used for lower affinity interactions.
To generate probes, one strand of DNA oligonucleotide was end-labeled
with polynucleotide kinase and γ-P32 ATP, and then annealed to the
unlabeled complimentary strand. For some experiments, only labeled DNA
was used and concentrations were determined with Quant-it PicoGreen from
Invitrogen. For other experiments, the labeled DNA was used a tracer with
known quantities of unlabeled DNA. Similar results were obtained with
these methods.
Acknowledgements
We thank S. Soni for providing purified recombinant protein, and N. Gnanapragasam
and C. Deligianni for primary cell protocol advice. We thank T. Ganz, S. Rivella,
N. Andrews, D. Higgs, H. Drakesmith, C. Roy and A. Goldfarb for discussion. We
thank S. Ghaffari, J. Little and C. Deligianni for comments on the manuscript.
Competing interests
The authors declare no competing or financial interests.
Author contributions
A.P., L.X., C.D.T., M.D., K.G., M.S. and D.N. performed experiments. L.L.P. and
A.C.P. provided data and analysis. J.J.B. directed experiments, provided data and
analysis, and wrote the manuscript with input from all authors.
Funding
This work was supported by two National Institutes of Health Public Health Service
grants (R01 DK46865 to J.J.B. and R01 DK100692 to L.L.P.), by a National Science
Centre grant (2013/09/B/NZ1/01879 to M.S.), by a National Health and Medical
Research Council grant (APP1082429 to A.C.P.) and by a grant from the National
Cancer Institute to the Jackson Laboratory (P30 CA034196). C.D.T. was
supported by the National Institutes of Health Intramural Research Program of the
National Institute of Diabetes and Digestive and Kidney Diseases. D.N. is an
American Society for Hematology Scholar. Deposited in PMC for release after
12 months.
Data availability
The RNA-seq data referred to in this study (Gillinder et al., 2016) are available from
Gene Expression Omnibus (GEO) under accession GSE71396.
Supplementary information
Supplementary information available online at
http://dev.biologists.org/lookup/doi/10.1242/dev.145656.supplemental
References
Adelman, C. A., Chattopadhyay, S. and Bieker, J. J. (2002). The BMP/BMPR/
Smad pathway directs expression of the erythroid-specific EKLF and GATA1
transcription factors during embryoid body differentiation in serum-free media.
Development 129, 539-549.
Andrews, N. C. (2009). Genes determining blood cell traits. Nat. Genet. 41,
1161-1162.
Arnaud, L., Saison, C., Helias, V., Lucien, N., Steschenko, D., Giarratana, M.-C.,
Prehu, C., Foliguet, B., Montout, L., de Brevern, A. G. et al. (2010). A dominant
mutation in the gene encoding the erythroid transcription factor KLF1 causes a
congenital dyserythropoietic anemia. Am. J. Hum. Genet. 87, 721-727.
Bieker, J. J. (2001). Kruppel-like factors: Three fingers in many pies. J. Biol. Chem.
276, 34355-34358.
Bieker, J. J. and Southwood, C. M. (1995). The Erythroid Krüppel-like Factor
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